Evidence map›Paper›PMID 41577813›Full record

ArticleNPJ precision oncology2026

Identification and characterization of MARCO-expressing tumor-associated macrophages in pancreatic ductal adenocarcinoma with pan-cancer relevance.

Hao Sun, Mengya Gao, Zexing Liu, Zhen Zhang, Xudong Li, Hong Huang, Tiandong Li, Jianxiang Shi, Jiaqin Yan, Mingxia Sun and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Hao Sun *Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Mengya Gao *Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Zexing Liu *Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Zhen Zhang *Department of Abdominal and Pelvic Tumor Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xudong LiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Hong HuangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Tiandong LiPrenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University/Maternal and Child Health Hospital of Henan Province, Zhengzhou, China.
Jianxiang ShiHenan Institute of Medical and Pharmaceutical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan, China.
Jiaqin YanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mingxia SunSchool of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Miao LiuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Yu AnDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Siyue LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yupeng LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhenghua HuangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuhan HuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuxuan LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chaoge LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mengmeng LiuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Meimei YanDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Junfeng ChuDepartment of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Yongping SongDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jinxin MiaoAcademy of Chinese Medicine Science, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Mengjia LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhilei BianDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wei LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Gangcheng WangDepartment of Abdominal and Pelvic Tumor Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. gangcheng07@hotmail.com.
Binglei ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zhangbinglei@zzu.edu.cn.
Shiyu ZuoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zuoshiyu0826@zzu.edu.cn.
Linping XuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyyxulinping1475@zzu.edu.cn.

Funding

Henan Province Medical Science and Technology Research Project LHGL20240207Henan Province Medical Science and Technology Research Project SBGJ202002087Henan Provincial Key R&D Program 251111312100Leading talent project of Henan Province LJRC2023004Natural Science Foundation of China 82270149Natural Science Foundation of China 82370144Natural Science Foundation of China 82400233Postdoctoral Innovative Talent Support Program GZC20232429The Natural Science Foundation of Henan Province 242300421080
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. The role of macrophage receptor with collagenous structure (MARCO), a scavenger receptor class-A protein expressed on macrophage surface, in PDAC progression remains unclear. Here, we identified a subset of MARCO-expressing macrophages with strong immunosuppressive signatures that were markedly increased in PDAC patients. Analysis of MARCO

Identifiers

PMID41577813
PMCPMC12936124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.